CD47 antibodies, methods, and uses

An isolated antibody or antigen binding fragment thereof comprising the following properties:

• a. the antibody or antigen binding fragment specifically binds to CD47 by interacting with CD47 (SEQ ID NO:
• 21 excluding the signal sequence) amino acid residues:
• i. Q1, L3, N27, E29, E97, L101, T102, R103, and E104;
• ii. Y37, K39, R45, D46, T49, A53, L54, N55, K56, S57, T58, V59, P60, T61, T564, A66, and K67;
• iii. E35, K39, Y37, D46, 49, D51, A53, L54, K56, T58, V59, T99, L101, and T102;
• or
• iv. E29, Q31, N32, E35, V36, Y37, K39, N41, D46, D51, A53, E97, T99, E100, L101, T102, R103, and E104;
• b. the antibody or antigen binding fragment thereof prevents CD47 from interacting with signal-regulatory protein alpha (SIRP alpha);
• c. the antibody or antigen binding fragment thereof does not have significant platelet aggregation activity and
• wherein the antibody or antigen binding fragment thereof comprises a VH complementarity determining region 1 (CDR1) sequence set forth in SEQ ID NO:
• 9 or SEQ ID NO:
• 10, a VH CDR2 sequence set forth in SEQ ID NO:
• 11 or SEQ ID NO:
• 12, a VH CDR3 sequence set forth in SEQ ID NO:
• 13 or SEQ ID NO:
• 14, a VL CDR1 sequence set forth in SEQ ID NO:
• 15 or SEQ ID NO:
• 16, a VL CDR2 sequence set forth in SEQ ID NO:
• 17 or SEQ ID NO:
• 18 and a VL CDR3 sequence set forth in SEQ ID NO:
• 19 or SEQ ID NO:
• 20.